Dr. Petrylak on PSMA ADC for Patients with mCRPC

Video

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses the results of a phase II trial that examined prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (mCRPC) patients.

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses the results of a phase II trial that examined prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (mCRPC) patients.

Petrylak says these patients were given 2.5 mg/kg of PSMA ADC for three weeks. This dose was found to be too high in some patients and was reduced to 2.3 mg/kg. Safety, tumor response by PSA, circulating tumor cells (CTC), imaging, biomarkers and clinical progression were assessed during the study.

The results of this phase II study showed that the patients who expressed PSMA on circulating tumor cells and had a lack of neuroendocrine markers responded to the antibody, Petrylak says. The drug was fairly well tolerated: only some instances of neutropenia and peripheral neuropathy were reported.

Petrylak says a second cohort of patients that are naïve to chemotherapy is undergoing analysis.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD